Bioidentical hormones vs standard HRT: what is the difference?

Short answer

• “Bioidentical” means the hormone molecule is chemically identical to the hormone your body makes (usually estradiol and/or micronized progesterone).
• “Standard” or conventional HRT includes FDA‑approved products that may be either bioidentical (e.g., estradiol, micronized progesterone) or non‑bioidentical (e.g., conjugated equine estrogens, synthetic progestins).
• The main practical differences are in regulation, quality control, evidence about safety and effectiveness, and how the product is prepared (manufactured vs compounded).

Key points

1. What “bioidentical” usually means

• Refers to hormones with the same chemical structure as human hormones (eg, 17β‑estradiol, progesterone).
• Available both as FDA‑approved manufactured products and as custom‑made compounded preparations from compounding pharmacies. Examples of FDA‑approved “bioidentical” products: Estrace (oral estradiol), Vivelle‑Dot/Climara/Alora (estradiol patches), EstroGel/Evamist (topical estradiol), and Prometrium (micronized progesterone).

1. What “standard” HRT includes

• FDA‑approved options with known dosing, manufacturing standards, and clinical trial data. Some are bioidentical (see above); others are not (eg, Premarin — conjugated equine estrogens; Prempro — conjugated estrogens + medroxyprogesterone). Provera (medroxyprogesterone acetate) is a commonly used synthetic progestin.

1. Regulation and quality control

• FDA‑approved products: manufactured under strict quality controls, have standardized dosing, and have been studied for efficacy/safety.
• Compounded bioidentical hormone therapy (custom mixes such as “bi‑est” or “tri‑est” or individualized doses): not FDA‑approved, variable potency and purity, limited large‑scale safety data. The FDA and medical societies warn about these limitations.

1. Evidence on safety and risks

• Risks such as venous thromboembolism, stroke, and (in some studies) breast cancer vary by hormone type, dose, route (oral vs transdermal), patient age and how long since menopause. For example, transdermal estradiol may have lower clot risk than oral estrogen in some studies.
• The Women’s Health Initiative (WHI) raised important safety questions about some HRT combinations (esp. conjugated estrogens + medroxyprogesterone). That evidence applies to specific products/doses and to average results in a population — individual risks vary.
• There is no convincing high‑quality evidence that compounded bioidentical mixes are safer or more effective than FDA‑approved HRT.

1. Testing and monitoring

• Routine salivary “hormone level” testing for tailoring HRT is not supported by good evidence; saliva tests are unreliable for guiding therapy. Blood estradiol or progesterone tests can be useful in specific clinical contexts but are not required for most standard dosing decisions. Follow clinical symptoms and routine safety monitoring (blood pressure, lipid profile, mammography as indicated).

1. Practical pros and cons

• FDA‑approved HRT: consistent dosing, quality control, evidence base — generally recommended as first choice. Examples: Estrace, Vivelle‑Dot, Climara, Prometrium, Premarin/Prempro (when those specific hormone formulations are chosen).
• Compounded bioidentical HRT: may offer customized doses or delivery forms; may be used when an individual truly cannot use available manufactured products. Downsides: variable quality, cost, limited data, insurance may not cover.

Recommendations (what you can do next)

• Talk with a clinician experienced in menopause care (OB/GYN, endocrinologist, or a provider affiliated with the North American Menopause Society). If you want a telemedicine option, services such as Mayo Clinic online consults, Maven Clinic, or local women’s health clinics can connect you to specialists.
• Prefer FDA‑approved products when possible (examples: Vivelle‑Dot, Climara, Estrace, EstroGel, Prometrium) because of known dosing and safety data. If a compounded product is being considered, use a reputable compounding pharmacy accredited by USP/NAPRA or your local board of pharmacy and discuss the limited evidence and risks.
• Discuss your medical history (age, time since menopause, clotting history, breast cancer risk, cardiovascular risk) to choose type, dose, and route that best balances symptom relief and safety.

Where to read reliable guidance

• North American Menopause Society (menopause.org) — clinical position statements and patient info.
• U.S. Food and Drug Administration — consumer updates on compounded bioidentical hormones.
• Mayo Clinic and American College of Obstetricians & Gynecologists patient information pages.

If you want, tell me: your main symptoms, age/time since menopause, and any relevant medical history (blood clots, breast cancer, heart disease) and I can outline the specific pros/cons of particular FDA‑approved options that would commonly be considered for someone like you.